Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
One Percent Rule Checklist For Safer Forex Trading Risk 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
LOS ANGELES, April 20, 2017 -- Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq:LBIO) concerning possible violations of federal securities laws between November 14, 2013 and April 10, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired the Company’s shares during the Class Period should contact the firm prior to the June 13, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, during the Class Period, Lion made false and/or misleading statements and/or failed to disclose: that the Company, through its former Chief Executive Officer (“CEO”) Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions; that former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about the Company on investment websites and to coordinate the distribution of articles to thousands of electronic mailboxes; that former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion was indirectly compensating them for their publications; and that as a result of the above, Lion’s public statements were materially false and misleading at all relevant times.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
